D. Boral Capital reaffirmed their buy rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a research note released on Thursday morning,Benzinga reports. They currently have a $17.00 target price on the stock.
Several other equities analysts also recently commented on the company. HC Wainwright initiated coverage on Immunic in a research report on Monday, November 25th. They issued a “buy” rating and a $10.00 target price on the stock. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a research report on Monday, February 10th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $12.67.
Get Our Latest Analysis on Immunic
Immunic Stock Up 6.6 %
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of IMUX. Connor Clark & Lunn Investment Management Ltd. raised its position in Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after purchasing an additional 42,383 shares during the last quarter. State Street Corp grew its holdings in Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after acquiring an additional 11,642 shares during the period. Jane Street Group LLC grew its holdings in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares during the period. Virtu Financial LLC acquired a new stake in Immunic during the 3rd quarter worth about $50,000. Finally, HB Wealth Management LLC acquired a new stake in Immunic during the 4th quarter worth about $81,000. 51.82% of the stock is owned by institutional investors.
About Immunic
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Further Reading
- Five stocks we like better than Immunic
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- What is a Dividend King?
- DuPont’s Electronics Spinoff: The Start of Something Big
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.